Detection and identification of pyrovalerone and its metabolite, a hydroxyla(ed product, are described. Their identities were confirmed by comparing their mass spectra and gas chromatographic retention times with those of the synthetic standards. The analytical method of pyrovalerone and its metabolite in biological samples was developed. The detection limit of the two compounds was 5 ng/mL, and the standard curves were linear in the concentration range of 10-5000 ng/mL The single dose kinetics of pyrovalerone and the metabolite in rat urine and plasma were studied (n = 3). The calculated first half-life time of pyrovalerone in ral plasma was 0.34 h, and the second half-life time was 1.50 h. The half-life time of the metabolite was 0.39 h. The two products were detected in rat urine up to 18 h after a single oral administration and are suggested as screening target compounds in dope analysis.
Introduction
Pyrovale tone [1-(4-methylphenyl )-2-( 1-pyrrolidinyl)-1-pentanone}, which is not permitted for use by athletes according to the regulations of the International Olympic Games, is a psychostimulant. In a previous experiment, Michaelis et al. (1) found that pyrovalerone was metabolized to its acidic form by humans, rabbits, and mice. The other acidic metabolites were described in our previous metabolism study (2) .
The present study reports the identification of a new basic metabolite and pyrovalerone in rat urine and plasma. In addition, simultaneous detection of the two compounds and their pharmacokinetics was described.
Experimental Chemicals
Pyrovalerone and pentazocine [ 1, 2, 3, 4 ,5,6-hexahydro-6,11-di-*Author to whom corresponderpce should be addressed.
methyl-3-(3-methyl-2-butenyl)-2, 6-methano-3-benzazocine-8-ol], which was chosen as the internal reference standard, were supplied by Eli Lilly (Indianapolis, IN). Methyliodide was purchased from Aldrich (Milwaukee, WI), and N-methyl-Ntrimethylsilyl trifluoroacetamide, MSTFA), 4-bromovalerophenone, and N-methyl-2-pyrrolidone were obtained from Sigma (St. Louis, MO). The following reagents were used: diethyl ether, diethylacetone, methanol, n-pentane chloroform, sodium sulfate, and isopropanol (Merck, Darmstadt, Germany). 
Synthesis of the hydroxylated metabolite

Stock solution
Standard solutions of pyrovalerone, hydroxylated metabolite, and pentazocine (1 mg/mL) were prepared by adding 10 mg of the drugs to 10 mL methanol; they were then stored at 4~ Under these conditions, the solutions were stable for several weeks. Working solutions of 10 and 1 tJg/mL were prepared by sequential dilutions. 
Drug administration and sample collection
Male Wister rats weighing 250-300 g were used. Pyrovalerone was given to rats orally at a dose of 20 mg/kg as 5 mg/mL in distilled water. Urine samples were collected at 0 (blank), 5, 12, 13, and 18 h, and blood samples were collected at 0 (blank), 0.25, 0.50, 0.75, 1.00, 1.50, 2.50, 4.50, and 8.00 h. Control urine was collected for 12 h before drug administration.
Extraction procedure
For each analysis 0.1 mL of rat plasma and 1.0 mL of rat urine were used. 10 IlL of 10 IJg/mL of pentazocine solution were added as internal standard to each sample of plasma or urine in a glass centrifuge tube. Seven milliliters of pentane-isopropanol (97:3) and 100 ~L of 5N NaOH were added; tubes were then stoppered and shaken mechanically for 20 rain and centrifuged for 5 rain at 750 • g.
The organic layer was transferred to a 15-mL glass centrifuge tube. HCI (0.5 mL, 0.2N) was added, and extraction was performed by mixing 10 rain in a mechanical shaker. The solution was centrifuged for 5 rain at 750 • and the organic layer was aspirated and discarded.
The aqueous layer was alkalinized with 5N NaOH to pH 14, re-extracted with 7 mL of distilled ether by shaking for 20 rain, and centrifuged for 5 rain at 750 xg. The organic layer was transferred into another tube and evaporated to dryness at reduced pressure.
Calibration curve and quantitation
The standard curves of pyrovalerone and the hydroxylated metabolite were established by adding 1, 5, 25, 50, 100, 250, and 500 ng of the authentics and 100 ng pentazocine to 0.1 mL of drug-free plasma or 1 mL of control urine. The ratios of the peak areas for pentazocine were used to calculate the calibration curves, the slope of which was used in the quantitation of the drugs in plasma or urine samples.
Trimethylsilylation
The residues were dissolved in 100 pL of MSTFA. The reaction mixtures were heated to 60~ for 10 rain and analyzed by gas chromatography-mass spectrometry (GC-MS).
Methylation
The residues were dissolved in 100 IJL of dry acetone and added to 20 ilL of CH3I and 100 mg of K2CO 3. The reaction mixtures were heated overnight at 60~ and analyzed by GC-MS.
GC
All GC experiments were performed with a Hewlett-Packard (Rockville, MD) 5890A gas chromatograph with a nitrogen-phosphorus detector (NPD). All injections were made by an HP 7673A autosampler. GC conditions for the plasma and urine analyses are given in Table I .
GC-MS
Most of the mass spectra were obtained with an HP 5890/5971 instrument. The same GC conditions as described above were also used for GC-MS. Chemical ionization (CI) mass spectra were obtained with an HP 5890/5988 GC-MS instrument. Methane was used as the reagent gas in the ion source. The electron energy was 230 eV. 5 . Chromatograms of rat plasma extracts. A, Blank plasma; 13, plasma to which 250 ng/mL of pyrovalerone was added; C, plasma to which 20 mg/kg was dosed orally. Peak identification: 1, pentazocine (internal standard); 2, pyrovalerone; 3, metabolite of pyrovalerone.
Nuclear magnetic resonance
All spectra were recorded on an 1H nuclear magnetic resonance (NMR) spectrometer Gemini-300 BB (Varian, Palo Alto, CA). CDC13 was used as the internal standard.
Results and Discussion
Identification of pyrovalerone and its metabolite in rat urine
When an aqueous solution of pyrovalerone was administered to rats, the parent drug (peak A) and a new metabolite (peak B) were detected in the basic extract from the rat urine. Figures 1 and 2 show the electron ionization (EI) mass spectra of the two peaks. Peak A showed the same retention time as authentic pyrovalerone. The EI and CI mass spectra of the compound (peak A) were identical to those of authentic pyrovalerone. The EI mass spectrum showed the base peak at re~z, and 126 other diagnostic ions at m/z 91,119, 127, and 202. The CI mass spectrum of peak A gave m/z 246 (M++I), 274 (M+C2Hs+), and 286 (M+C3H5 +) and principal fragment ions at m/z 126 and 202. The peak gave no difference in the retention time and mass spectrum after methylation or silylation. This shows that pyrovalerone does not have functional group to be derivatized with MSTFA or CH3I. Peak B had a retention time longer than that of pyrovalerone. The EI mass spectrum of the compound showed the base peak at m/z 126 and other diagnostic ions at m/z 107, 127, 135, and 218. The CI mass spectrum of peak B gave m/z 262 (M++I), 290 (M+C2H5+), and 302 (M+C3H5 +) and principal fragment ions at m/z 126 and 218. Most of the diagnostic ions of peak B were increased by m/z 16. The mass spectral data suggest the presence of a hydroxyl group in the ring-containing part of the metabolite. There are two possibilities for hydroxyl group substitution: on the aromatic ring or at the benzylic position of pyrovalerone. In general, a phenolic hydroxyl group is easily methylated with methyliodide, whereas an aliphatic hydroxyl group is not. However, both aliphatic and phenolic hydroxyl groups are trimethyl silylated with MSTFA (3). The hydroxylated metabolite was not derivatized with methyl iodide but it was derivatized with MSTFA from our experiment. The mass spectrum of the trimethylsilylated derivative is shown in Figure 3 . The GC chromatogram of the derivative showed the shift of 1.5 min from retention time of the underivatized metabolite. The El mass spectrum showed the characteristic fragment at m/z 318 (M+-15) from the loss of a methyl group from the molecular ion and m/z 73 from TMS. Also, m/z 126 was formed from fragmentation at the same position as that in case of pyrovalerone. The identity of the metabolite was finally confirmed by comparison of the EI-MS and the GC retention time of the synthetic standard. From the mass spectra of synthetic substance, we found the same base peak and diagnostic ions as those of the new metabolite. The 1H NMR data of the synthetic hydroxylated pyrovalerone are reported in Table II .
The spectrum was similar to that of pyrovalerone, but integration of the signal at 5 = 7.33 ppm gave only one proton, indicating the substitution of an hydroxyl group at oc-position of the phenyl ring. From the data, peak B was identified as hydroxylated pyrovalerone as shown in Figure 4 . 
Extraction prodedure
The gas chromatogram obtained from plasma to which a known amount of pyrovalerone was added is shown in Figure  5 , together with those obtained from a plasma blank and plasma dosed orally. No interfering peak from any endogenous substance was present in the peaks of pyrovalerone, the metabolite, and pentazocine. Plots of standard curves of the drugs over the described concentration range were linear. The line of best fit for pyrovalerone, using the internal standard pentazocine, was y = 0.0095x + 0.0184 (r = 0.9998), where x is the analyte concentration and y is the peak-area ratio. The lower detection limit of the two compounds in 0.1 mL plasma was 5 ng/mL (calculated as signal:noise ---3). The coefficients variation and the recoveries of the method at several concentrations are reported in Tables III and  IV , respectively. The analytical data obtained from a urine sample were similar to those from a plasma sample.
Elimination of pyrovalerone and its metabolite
The described analytical method was used to study the pharmacokinetic of pyrovalerone and its metabolite. The plasma concentration-time curves over 8 h are presented in Figure 6 . Absorption of pyrovalerone was very rapid. The calculated first half-life time of pyrovalerone in plasma was 0.34 h, and the second half-life time was 1.50 h. The calculated half-life time of the hydroxylated metabolite in plasma was 0.39 h. The excretion curves of pyrovalerone in rat urine are shown in Figure  7 . The total amounts of the pyrovalerone and the identified metabolite recovered during 20 h were approximately 0.20 and 0.15% of the dose (n = 3).
Conclusion
Many athletes use performance-enhancing substances in an effort to gain an unfair competitive advantage. The use of performance-enhancing drugs by athletes threatens the integrity of amateur sport. The development of analytical methods and metabolism studies for the drugs is necessary for the screening of abuse drugs. Pyrovalerone is banned for athletes according to IOC regulation, but no one has described a screening method for the drug. We suggest that the hydroxylated metaboJournal of Analytical Toxicology, Vol. 20, November/December 1996 lite and parent compound can be used as screening target compounds, even though additional human metabolism studies must be performed. This screening method for pyrovalerone can be recommended for volatile compounds using gas-liquid chromatography with NPD (4).
